Clinical trial

Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients.

NCT03381417

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2016-10-06

PhasePHASE3

Study timeline

Study start (actual)2016-10-06Date precision: day

Registry last updated2018-01-02

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancer Femaleunresolved

Interventions

pegcyteDRUG

NeulastimDRUG

Sponsors & collaborators

Nanogen Pharmaceutical Biotechnology Joint Stock Companylead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03381417 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.